Eurofins Panlabs Adds U.S. Jobs to its Midwest Headquarters
December 30, 2015
By Alex Keown, BioSpace.com Breaking News Staff
ST. LOUIS – Eurofins Panlabs, a company that uses data analytics to predict the clinical effects of drugs, is adding 10 jobs to its Missouri headquarters, the St. Louis Business Journal reported this morning.
Christina Shasserre, a vice president with Eurofins Pharma Discovery and Bioanalytics Services U.S., told the Journal the addition of 10 positions is due in large part to the “high-caliber institutions in the region such as Washington University, St. Louis University, University of Missouri and other regional universities.” The 10 new positions will increase the number of employees at the Missouri facility to 55, the Journal said. There was no information provided about what type of positions are being created and the salary range.
Eurofins Panlabs is a division of Eurofins Pharma Discovery and Bioanalytics Services, which provides more than 1,500 drug discovery products. In October, Eurofins launched a new online platform to allow research scientists it contracts with to “order the highest quality kits, protein, enzymes and cell-based reagents.” The product portfolio includes the largest number of human kinase proteins and the largest portfolio of ubiquitin pathway proteins, plus Epigenetic regulators, GPCRs, and Ion Channels, all critical in drug discovery research, Eurofins said in a statement.
Some of those proteins include new epigenetic proteins that were launched in August. Due to the growing biological relevance of epigenetic targets for therapeutic intervention, Eurofins developed an epigenetic screening and profiling service with a broad portfolio of proteins including Readers, Writers, Erasers and Cell-based assays, the company said in a statement. With the launch of the new epigenetic proteins, the company said the “same high quality proteins used in the services provided by Eurofins for pharmaceutical clients” are now available for direct purchase for internal discovery research.
In 2014, Eurofins reported revenue of $1.5 billion, the Journal said.
In June, Eurofins Scientific, another division of Eurofins Pharma Discovery, inked a $50 million deal to acquire Diatherix Laboratories. Eurofins said Diatherix strengthens its growing footprint in the specialty clinical diagnostics market. Eurofins said it expected the deal to generate about $40 million in 2015.
A decision was reached in September in a legal battle between Eurofins and France-based Onxeo S.A. over the transfer of a phenotyping technology to diagnose resistance to antiviral drugs. The two companies struck a deal in 2005 to transfer the licensing rights to Eurofins. Eurofins claimed that the value of the assets sold was compromised by the rights of a third party, which rights had been hidden at the time of the sale and demanded a termination of the contract. This year the Paris Commercial Court considered that Onxeo did not fulfill its contractual disclosure obligation towards Eurofins but at the same time has held that Eurofins owed the same amount to Onxeo under the contract as the price of the Option. The court set-off the amounts owed by the companies to each other so that neither of them has to make a payment to the other.